Matching-adjusted indirect comparison (MAIC) of relative efficacy for brigatinib vs. ceritinib and alectinib in crizotinib-resistant anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC).

Karen L. Reckamp,Joseph Lee,Joice Huang,Irina Proskorovsky,William Reichmann,Mira Krotneva,David Kerstein,Hui Huang

Matching-adjusted indirect comparison (MAIC) of relative efficacy for brigatinib vs. ceritinib and alectinib in crizotinib-resistant anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC).

2017

Karen L. Reckamp
Joseph Lee
Joice Huang
Irina Proskorovsky
William Reichmann
Mira Krotneva
David Kerstein
Hui Huang

e20675Background: Brigatinib (BRG), ceritinib (CER), and alectinib (ALEC) are second-generation ALK inhibitors developed for crizotinib (CRZ)-resistant ALK+ NSCLC. No randomized trial has directly ...

Keywords:

non-small cell lung cancer (NSCLC)
Brigatinib
Ceritinib
Pathology
Alectinib
Crizotinib
Medicine
Cancer research
Anaplastic lymphoma kinase
relative efficacy
Randomized controlled trial
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations